Year

2012
River Vision Development Corp. today announced the completion of a Series A financing, raising $17 million for the development of a novel protein therapy, RV 001, for the treatment of Graves' Orbitopathy (GO). GO is a condition afflicting a proportion of Graves' Disease patients, in which an autoimmune response is mounted against tissues behind the...
  Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has dosed the first European patient in its ongoing international Phase 2b clinical trial of MYDICAR, Celladon's first in class therapeutic for the treatment of advanced heart failure (HF). The Phase 2b study...
New hope for patients who suffer major depression without finding relief from antidepressants   Nexstim Oy, a medical device company, announced today that the Navigated Brain Therapy (NBT) System meets the requirements of the European Medical Devices Directive (MDD).The NBT System is the first non-invasive, non-systemic therapeutic device CE-marked to offer patients a personalized treatment...
  Veloxis Pharmaceuticals A/S (OMX: VELO) today announced results of a preliminary analysis from the first 16 patients in its Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO) clinical trial. Results from the first 16 patients demonstrated a trend toward a reduction in tremor following the switch from twice-daily tacrolimus to once-daily LCP-Tacro....
BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced today that it has been selected as a Top 100 Winner for Red Herring’s 2012 Global Award in recognition as a leader in innovation and technology among private companies from North America, Europe and...
Chronic infections are a growing problem in our world. The bacteria clump together, which protects them against both antibiotics and the body's immune system. The recently appointed Lundbeck Foundation Fellow, Thomas Bjarnsholt, is trying to learn more about bacterial fortresses to make it easier to fight them in future.
  ‘OCTAVE’ Study Will AssessColoAd1in Patients with Ovarian Cancer   PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, today announced the award of a £1.7 million ($2.7 million) grant from the UK government-backed Biomedical Catalyst to initiate a Phase I/II clinical trial to assess the use of ColoAd1 in the treatment of platinum-resistant, recurrent...
Last night the Lundbeck Foundation awarded more than DKK 80 million to promising young talents in the Danish research community. The Foundation also announced that it will recommend that CEO Steffen Kragh becomes a new member of the Board.
The Lundbeck Foundation now invites applications for five fellowships within biomedicine and two within natural sciences which will be granted to especially promising young researchers and their research groups. Read more here: LF_Science_031012_177x120.pdf
  Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that it has entered into an exclusive distribution agreement with Chiesi Farmaceutici S.p.A, a fully integrated European Pharmaceutical company focused on respiratory disease and special care products, for the commercialization and distribution of its novel formulation immunosuppressant drug candidate LCP-Tacro in certain countries, including Europe, Turkey and...
1 2 3 5

News

Danish scientists shed new light on overwhelming need to sleep
19. February 2019
Largest study yet links so-called cat-poo parasite to schizophrenia
2. February 2019
Scientists identify links between psychiatric disorders and events during the foetal stage
28. January 2019

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge